Clinical Trial: Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
Study Status: Completed
Recruit Status: RECRUITING
Condition: Chronic Lymphocytic Leukemia
Study Type: INTERVENTIONAL
Official Title: Addition of loNcasTuxImab teSirine to AcalabruTinib in Chronic Lymphocytic Leukemia(Anti-Static Study)
Brief Summary:
Study is a phase I study to determine the maximum tolerated dose of adding Loncastuximab Tesirine to Aclabrutinib in the treatment of chronic lymphocytic leukemia.
Read more